Explore
Validate
LearnAP11217PU-N
antibody from Acris Antibodies GmbH
Targeting: SUMO1
GMP1, OFC10, PIC1, SMT3C, SMT3H3, SUMO-1, UBL1
Western blot
ImmunocytochemistryAntibody data
- Antibody Data
- Antigen structure
- References [0]
- Comments [0]
- Validations
- Western blot [2]
- Immunohistochemistry [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- AP11217PU-N - Provider product page
- Provider
- Acris Antibodies GmbH
- Proper citation
- Acris Antibodies GmbH Cat#AP11217PU-N, RRID:AB_1771343
- Product name
- anti SUMO1 (C-term)
- Antibody type
- Polyclonal
- Antigen
- This antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide selected from the C-terminal region of human SUMO1.
- Reactivity
- Human, Mouse
- Host
- Rabbit
- Vial size
- 0.4 ml
- Concentration
- lot specific
No comments: Submit comment
Supportive validation
- Submitted by
- Acris Antibodies GmbH (provider)
- Main image
- Experimental details
- western Blot analysis using anti-SUMO1 polyclonal antibody (Cat.#AP11217PU-N) to detect GST-SUMO1 fusion protein.
- Submitted by
- Acris Antibodies GmbH (provider)
- Main image
- Experimental details
- COS-7 cells were transfected for 24 hrs with a plasmid expressing FLAG-ERM (left panels) or FLAG-ERM KR12345 (right panels). Untreated (-) and H2O2-treated (+) cells were collected for immunoblot analysis. Top panels: cell lysates probed by western blot (WB) with an anti-ERM antibody. Center panels: cell lysates immunoprecipitated (IP) with an anti-FLAG antibody followed by WB with AP11217PU-N SUMO-1 antibody. Bottom panels: cell lysates immunoprecipitated with an anti-FLAG antibody followed by WB with AP11224PU-N SUMO-2/3 antibody. (*) represents immunoprecipitated ERM-like forms recognized by anti-SUMO antibodies.
Supportive validation
- Submitted by
- Acris Antibodies GmbH (provider)
- Main image
- Experimental details
- Formalin-fixed and paraffin-embedded human cancer tissue reacted with the primary antibody, which was peroxidase-conjugated to the secondary antibody, followed by DAB staining. This data demonstrates the use of this antibody for immunohistochemistry; clinical relevance has not been evaluated.
